zPremium - Thursday afternoon was our latest Healthcare Huddle webinar. We covered ongoing ideas, but focused afterwards on a slew of CNS-focused companies that are worth looking … Continue Reading
Premium: Read NowResearch - Shares of Sage Therapeutics (SAGE) fell today on news that data from STATUS — the company’s phase 3 study of SAGE-547 in SRSE – would … Continue Reading
Premium: Read NowResearch - Ionis (IONS) gained about $1.2 billion in market value this week when a phase 3 study of nusinersen, the company’s antisense drug for Spinal Muscular … Continue Reading
Premium: Read NowResearch - We’ve been discussing the potential for biotech to play some catchup to the broader market in our monthly webinars of late, and the move is … Continue Reading
Premium: Read NowResearch - A last-minute trade idea for this slow Friday afternoon. As most healthcare investors will be aware, Sanofi (SNY) has made public their desire to purchase … Continue Reading
Premium: Read NowResearch - In investing and trading, understanding where expectations stand for a company or equity is half the battle. In the case of large, profitable listed companies, that’s often earnings expectations: a beat is only a beat because it topped market expectations. In the case of bio/pharma stocks, we make the same evaluations for binary events, like mid-stage study results.
Read NowResearch - ASCO abstracts were made public on Wednesday evening, May 18. Here are some quick takes. ALTA Data for Brigatinib In ALTA, Ariad’s (ARIA) brigatinib produced … Continue Reading
Premium: Read Now
